Scientists Develop “Velcro” Cancer Treatment That Works Across Many Tumor Types

Researchers at the University of California, Irvine have developed an innovative cancer immunotherapy called GlyTR, a new class of treatment that uses a “velcro-like” mechanism to target sugar molecules abundantly present on cancer cells. Their findings were published in September 2025 in the prestigious journal Cell, marking a significant advancement in cancer immunotherapy.

Traditional immunotherapies typically target protein markers on cancer cells, but these proteins are often found at low levels in normal tissues, leading to side effects from damage to healthy cells. GlyTR takes a different approach by targeting tumor-associated carbohydrate antigens (TACAs), complex sugar chains present at much higher densities on cancer cells compared to normal cells. This difference in density allows GlyTR to selectively bind cancer cells while largely sparing healthy tissue.

Two bispecific protein compounds were created: GlyTR1, which targets β1,6GlcNAc-branched N-glycans, and GlyTR2, which targets multiple carbohydrate antigens, including Tn, sialyl-Tn, LacDiNAc, and GD2. These compounds combine lectin domains (proteins that bind specific sugar structures) with an antibody fragment that engages and activates T cells, the immune system’s cancer-killing cells. The multivalent, velcro-like binding enhances specificity by differentiating cells based on the density of the sugar molecules, a feature unlike traditional single-key antibody binding.

Extensive laboratory studies showed that GlyTR1 and GlyTR2 effectively directed T cells to attack a wide range of cancers, including breast, prostate, pancreatic, colon, lung, ovarian, and blood cancers such as leukemia. The treatment was effective even in immunosuppressive tumor environments characterized by regulatory T cells, inhibitory cytokines, and low oxygen levels, conditions where many immunotherapies fail. In humanized mouse models, the treatments did not cause toxicity to normal tissues even those expressing low levels of target sugars, supporting a strong safety profile.

The researchers note that GlyTR’s ability to target highly abundant glycans could be a solution to the challenge of finding cancer-specific, safe targets and eliminate the need for developing different therapies for each cancer type. GlyTR1 is already undergoing clinical-grade manufacturing at facilities affiliated with the National Cancer Institute’s Experimental Therapeutics program, and a Phase 1 clinical trial is planned within about two years, focusing on patients with metastatic solid tumors where glycan density is highest.

Source.